Multidrug-resistant tuberculosis in central Asia
Multidrug-resistant tuberculosis in central Asia
复制标题
DOI：
10.3201/eid1005.030718
复制
发表时间：
2004-05-01
影响因子：
11.8
通讯作者：
Aziz, M
中科院分区：
文献类型：
--
作者：
Cox, HS;Orozco, JD;Aziz, M
耐多药结核病（MDR-TB）已成为结核病控制的主要威胁，特别是在前苏联。为了确定无国界医生组织在中亚乌兹别克斯坦和土库曼斯坦两个地区支持的直接观察治疗策略（DOTS）计划中的耐药性水平，我们在卡拉卡尔帕克斯坦（乌兹别克斯坦）和达沙古兹（土库曼斯坦）的选定地区对痰检阳性结核病患者进行了横断面调查。在这两个区域都发现了高水平的耐多药结核病。在卡拉卡尔帕克斯坦，106名新患者中有14名（13%）感染了耐多药结核病; 107名以前接受过治疗的患者中有43名（40%）感染了类似的结核病。Dashoguz的比例分别为4%（4/105例患者）和18%（18/98例患者）。总体而言，在卡拉卡尔帕克斯坦，27%的涂片阳性患者通过DOTS方案接受治疗，在达沙古兹，11%的类似患者在入院时感染了耐多药结核菌株。这些结果表明，国际社会需要采取协调一致的行动，遏制耐多药结核病的传播并减少其影响。
Multidrug-resistant tuberculosis (MDR-TB) has emerged as a major threat to TB control, particularly in the former Soviet Union. To determine levels of drug resistance within a directly observed treatment strategy (DOTS) program supported by Medecins Sans Frontieres in two regions in Uzbekistan and Turkmenistan, Central Asia, we conducted a cross-sectional survey of smear-positive TB patients in selected districts of Karakalpakstan (Uzbekistan) and Dashoguz (Turkmenistan). High levels of MDR-TB were found in both regions. In Karakalpakstan, 14 (13%) of 106 new patients were infected with MDR-TB; 43 (40%) of 107 previously treated patients were similarly infected. The proportions for Dashoguz were 4% (4/105 patients) and 18% (18/98 patients), respectively. Overall, 27% of patients with positive smear results whose infections were treated through the DOTS program in Karakalpakstan and 11% of similar patients in Dashoguz were infected with multidrug-resistant strains of TB on admission. These results show the need for concerted action by the international community to contain transmission and reduce the effects of MDR-TB.